Lexicon Pharmaceuticals, Inc. LXRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lexicon Pharmaceuticals, Inc. (LXRX) is a healthcare company listed in the US with a market value of about $797M. In the twelve months to September 30, 2026 it had revenue of $39M and net income of -$62M, a net margin of -161.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 16% a year, a 5-year average ROIC of -55%.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $23M in 2014 to $50M in 2025, growth of about 7.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 119% over three years (dilution for shareholders). It spends 123% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $50M | $31M | $1M | $139000 | $298000 | $24M | $322M | $63M | $92M | $79M |
| Net income | -$62M | -$50M | -$200M | -$177M | -$102M | -$88M | -$59M | $130M | -$121M | -$123M | -$131M |
| Free cash flow | -$49M | -$68M | -$180M | -$162M | -$90M | -$88M | -$143M | $114M | -$149M | -$186M | -$176M |
| EPS (diluted) | $-0.14 | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-1.27 |
| Net margin | -161.8% | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -134.1% | -165.9% |
| ROIC | — | -22.8% | -61.8% | -68.1% | -46.2% | -75.9% | -22.4% | 30.5% | -36.5% | -32.3% | -47.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $4.51, 152% above the current price; targets range from $1.69 to $8.00; the consensus rating is “Buy”; expected EPS is $-0.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Lexicon Pharmaceuticals pay a dividend?
Not currently.
Is Lexicon Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Lexicon Pharmaceuticals scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.